A detailed history of Victory Capital Management Inc transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 14,403 shares of LYEL stock, worth $9,650. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,403
Previous 15,296 5.84%
Holding current value
$9,650
Previous $22,000 13.64%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$1.13 - $1.88 $1,009 - $1,678
-893 Reduced 5.84%
14,403 $19,000
Q2 2024

Aug 05, 2024

SELL
$1.3 - $3.01 $62 - $144
-48 Reduced 0.31%
15,296 $22,000
Q1 2024

May 03, 2024

SELL
$1.71 - $3.07 $2,180 - $3,914
-1,275 Reduced 7.67%
15,344 $34,000
Q4 2023

Feb 05, 2024

BUY
$1.39 - $2.35 $4,694 - $7,935
3,377 Added 25.5%
16,619 $32,000
Q3 2023

Nov 06, 2023

BUY
$1.45 - $3.35 $198 - $458
137 Added 1.05%
13,242 $19,000
Q2 2023

Jul 27, 2023

SELL
$1.89 - $3.86 $572 - $1,169
-303 Reduced 2.26%
13,105 $41,000
Q1 2023

May 02, 2023

BUY
$1.97 - $3.58 $26,413 - $48,000
13,408 New
13,408 $31,000
Q2 2022

Aug 01, 2022

SELL
$3.68 - $6.8 $623,576 - $1.15 Million
-169,450 Reduced 87.97%
23,167 $151,000
Q1 2022

May 04, 2022

SELL
$5.05 - $7.7 $69,493 - $105,959
-13,761 Reduced 6.67%
192,617 $975,000
Q4 2021

Feb 07, 2022

SELL
$7.13 - $15.19 $24,997 - $53,256
-3,506 Reduced 1.67%
206,378 $1.6 Million
Q3 2021

Nov 02, 2021

BUY
$11.0 - $17.95 $187,484 - $305,939
17,044 Added 8.84%
209,884 $3.11 Million
Q2 2021

Aug 03, 2021

BUY
$15.99 - $16.89 $3.08 Million - $3.26 Million
192,840 New
192,840 $3.13 Million

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $166M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.